<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02128113</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 408-C-1309</org_study_id>
    <nct_id>NCT02128113</nct_id>
  </id_info>
  <brief_title>RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD</brief_title>
  <official_title>A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408)&#xD;
      ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many ocular diseases are characterized by oxidative stress and/or inflammation. Oxidative&#xD;
      stress is also known to adversely impact corneal endothelial cells, and may be a factor&#xD;
      resulting in the acute decrease in corneal endothelial cell density following ocular surgery.&#xD;
      While corticosteroids provide potent anti-inflammatory efficacy in a wide range of acute and&#xD;
      chronic inflammatory ocular diseases, their use is limited by their side effect profile,&#xD;
      which includes the potential to elevate IOP and induce cataract formation. In addition, most&#xD;
      available ophthalmic anti-inflammatory treatments, including corticosteroids, do not directly&#xD;
      protect against the underlying oxidative stress component of the disease process.&#xD;
      Consequently, there is a clinical need for agents that protect against oxidative stress and&#xD;
      provide anti-inflammatory efficacy without inducing steroid-like side effects.&#xD;
&#xD;
      This study will assess the safety and efficacy of omaveloxolone (RTA 408) Ophthalmic&#xD;
      Suspension (0.5% or 1%) versus vehicle for the prevention of corneal endothelial cell loss in&#xD;
      patients undergoing cataract surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of corneal endothelial cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>Count of corneal endothelial cells 12 weeks post cataract surgery, compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of inflammation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determine number of patients who have no inflammation 2 weeks post cataract surgery according to the Standardization of Uveitis Nomenclature (SUN) Working Group Inflammatory Scoring System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of pain</measure>
    <time_frame>1 day</time_frame>
    <description>Determine number of patients who have no pain 1 day post cataract surgery according to the National Institutes of Health (NIH) Numeric Pain Rating Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Corneal Endothelial Cell Loss</condition>
  <condition>Ocular Pain</condition>
  <condition>Ocular Inflammation</condition>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5% omaveloxolone (RTA 408) opthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% omaveloxolone (RTA 408) opthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Opthalmic suspension manufactured to mimic RTA 408 suspension</description>
    <arm_group_label>Placebo ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Omaveloxolone Ophthalmic Suspension</intervention_name>
    <description>0.5% ophthalmic suspension of RTA 408</description>
    <arm_group_label>0.5% omaveloxolone (RTA 408) opthalmic suspension</arm_group_label>
    <other_name>0.5% RTA 408 Ophthalmic Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Omaveloxolone Ophthalmic Suspension</intervention_name>
    <description>1% ophthalmic suspension of RTA 408</description>
    <arm_group_label>1% omaveloxolone (RTA 408) opthalmic suspension</arm_group_label>
    <other_name>1% RTA 408 Ophthalmic Suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be male or female and ≥18 years of age and ≤80 years of age&#xD;
&#xD;
          2. Plan to undergo cataract extraction by phacoemulsification with the implantation of a&#xD;
             posterior chamber intraocular lens&#xD;
&#xD;
          3. Have the potential, in the opinion of the investigator, to improve best-corrected&#xD;
             visual acuity in the study eye after surgery&#xD;
&#xD;
          4. Have Grade 3, 4, or 5 nuclear cataract in the study eye, according to the LOCS III&#xD;
&#xD;
          5. Have corneal endothelium in the study eye that can be accurately assessed using&#xD;
             specular microscopy&#xD;
&#xD;
          6. Have endothelial cell density of &gt;1800 cells/mm2 in the study eye at the Screening&#xD;
             Visit&#xD;
&#xD;
          7. Have a pinhole visual acuity (VA) of at least 1.0 logarithm of the minimum angle of&#xD;
             resolution (logMAR) in the study eye and fellow eye as measured using an Early&#xD;
             Treatment for Diabetic Retinopathy Study (ETDRS) chart&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a score &gt;0 on the ocular pain assessment at the Screening Visit or the&#xD;
             Randomization Visit in the study eye&#xD;
&#xD;
          2. Have an active immunosuppressive disease or an autoimmune disease that, in the opinion&#xD;
             of the investigator, could affect the quality of the ocular surface&#xD;
&#xD;
          3. Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and&#xD;
             will likely affect wound healing&#xD;
&#xD;
          4. Have an intraocular pressure (IOP) ≤5 mmHg in either eye&#xD;
&#xD;
          5. Have had corneal or retinal surgery (laser or incisional) within the past 6 months, or&#xD;
             be planning to have laser or incisional surgery during the study period in the study&#xD;
             eye&#xD;
&#xD;
          6. Have the presence of guttae Stage 2 or greater or other abnormality in the study eye&#xD;
             that does not allow for accurate corneal endothelial cell assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Eye Center</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Argus Research</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levenson Eye Associates</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chicago Cornea Consultants</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JacksonEye</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Vision Centers</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthalmic Consultants of Boston</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talamo Hatch Laser Eye Consultants</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Eye Care</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Eye Care</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alterman, Modi and Wolter</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R &amp; R Eye Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>See Clearly Vision Group</name>
      <address>
        <city>McLean</city>
        <state>Virginia</state>
        <zip>22102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <disposition_first_submitted>June 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 16, 2015</disposition_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>Cataract surgery</keyword>
  <keyword>Corneal Endothelial Cells</keyword>
  <keyword>omaveloxolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Corneal Endothelial Cell Loss</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

